PRKDC and cancer: Based on these results, the authors hypothesizedthat TP53-deficient cancer cells acquired resistanceto DNA-PK inhibitor peposertib thorough a compensatoryincrease of POLθ expression and MMEJ pathway, of which theybecame dependent, thus showing sensitivity to NVB.